Summary

Persistence Market Research recently published a comprehensive report on the global Pet Allergy Treatment Market, providing detailed insights into key market dynamics, trends, opportunities, and challenges shaping the industry.

Key Insights:

• Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
• Projected Market Value (2031F): USD 3,930.76 million
• Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Report Scope:

The market for pet allergy treatment addresses allergic reactions in pets, primarily cats and dogs, through various therapeutic options such as medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. It serves veterinary clinics, hospitals, pet care centers, and homecare settings, responding to the increasing demand for effective allergy management solutions globally.

Market Growth Drivers:

The global market is driven by rising pet ownership, heightened awareness of pet allergies, and advancements in veterinary medicine. Increasing prevalence of allergies among pets and their owners underscores the demand for effective treatments. Technological innovations in diagnostics and treatments enhance accuracy and efficacy. Expansion of pet insurance coverage and investments in pet healthcare infrastructure further propel market growth.

Market Restraints:

Despite growth prospects, challenges include regulatory compliance complexities, variable treatment outcomes, and pet owner adherence issues. Regulatory frameworks for veterinary pharmaceuticals and biologics impose compliance burdens, influencing market dynamics. High treatment costs and limited reimbursement in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

Demographic trends, pet humanization, and evolving consumer preferences offer growth opportunities. Integration of telemedicine and digital health solutions improves access to veterinary care. Collaborations among pharmaceutical companies, pet food manufacturers, and allergy specialists drive innovation. Investments in R&D and educational initiatives are crucial for capitalizing on emerging trends.

Key Questions Answered:

• Drivers of global pet allergy treatment market growth?
• Popular treatment modalities and diagnostic tools?
• Impact of technological advancements on market competitiveness?
• Key players and strategies for market leadership?
• Emerging trends and future prospects in the market?

Competitive Landscape:

Leading players focus on innovation, product differentiation, and strategic partnerships. R&D investments target novel therapies and diagnostic tests. Collaboration with regulatory agencies and pet insurance companies facilitates market access. Emphasis on evidence-based practice, veterinary education, and pet owner engagement supports sustainable growth.

Key Companies Profiled:

• Zoetis Animal Healthcare
• Merck and Co Inc.
• Boehringer Ingelheim GmbH
• Elanco Animal Health Incorporated
• Bayer AG
• Vetoquinol S.A.
• Dechra Pharmaceuticals PLC
• Virbac SA
• IDEXX Laboratories, Inc.
• Ceva Santé Animale
• Kindred Biosciences, Inc.
• Phirbo Animal Health
• Norbrook Laboratories Limited
• Vetiquinol SA
• Neogen Corporation
• PetIQ, Inc.
• Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:
• Antihistamines
• Corticosteroids
• Immunotherapy
• Antibiotics

By Indication:
• Allergic Dermatitis
• Food Allergy
• Fleabite Allergy
• Contact Allergy

By Pet Type:
• Dogs
• Cats
• Rodents & Rabbits

By Route of Administration:
• Oral
• Injectable
• Topical

By Distribution Channel:
• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption Analysis
4.2. Product USPs/Features Analysis, By Brands
4.3. Regulatory Landscape, By Country
4.4. Recent Product Approval/Launches
4.5. Disease Epidemiology
4.6. Porter’s Analysis
4.7. PESTLE Analysis
4.8. Value Chain Analysis
4.9. Unmet Needs
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Pharmaceutical Market Outlook
5.1.3. Global Animal Healthcare Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Rate of Pet Adoption
5.2.2. Increase in Research and Development
5.2.3. Strategic Collaborations among players
5.2.4. Cost of Product
5.2.5. Business Expansions
5.2.6. Frequency of Product Approval
5.2.7. Pet Care Insurance
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031
6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
7.3.1. Antihistamines
7.3.2. Corticosteroids
7.3.3. Immunotherapy
7.3.4. Antibiotics
7.4. Market Attractiveness Analysis By Drug Class
8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
8.3.1. Allergic Dermatitis
8.3.2. Food Allergy
8.3.3. Fleabite Allergy
8.3.4. Contact Allergy
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
9.3.1. Dogs
9.3.2. Cats
9.3.3. Rodents and rabbits
9.4. Market Attractiveness Analysis By Pet Type
10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
10.3.1. Oral
10.3.2. Injectable
10.3.3. Topical
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
11.3.1. Veterinary Hospitals
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.3.4. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
13.3.1. By Country
13.3.1.1. United States
13.3.1.2. Canada
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Pet Type
13.3.5. By Route of Administration
13.3.6. By Distribution Channel
13.4. Market Attractiveness Analysis By Region
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Indication
13.4.4. By Pet Type
13.4.5. By Route of Administration
13.4.6. By Distribution Channel
13.5. Market trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. United States Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug Class
13.8.1.2.2. By Indication
13.8.1.2.3. By Pet Type
13.8.1.2.4. By Route of Administration
13.8.1.2.5. By Distribution Channel
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug Class
13.8.2.2.2. By Indication
13.8.2.2.3. By Pet Type
13.8.2.2.4. By Route of Administration
13.8.2.2.5. By Distribution Channel
14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Pet Type
14.3.5. By Route of Administration
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis By Region
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Indication
14.4.4. By Pet Type
14.4.5. By Route of Administration
14.4.6. By Distribution Channel
14.5. Market trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug Class
14.8.1.2.2. By Indication
14.8.1.2.3. By Pet Type
14.8.1.2.4. By Route of Administration
14.8.1.2.5. By Distribution Channel
14.8.2. Mexico Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug Class
14.8.2.2.2. By Indication
14.8.2.2.3. By Pet Type
14.8.2.2.4. By Route of Administration
14.8.2.2.5. By Distribution Channel
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug Class
14.8.3.2.2. By Indication
14.8.3.2.3. By Pet Type
14.8.3.2.4. By Route of Administration
14.8.3.2.5. By Distribution Channel
15. Europe Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. France
15.3.1.3. Spain
15.3.1.4. Russia
15.3.1.5. Italy
15.3.1.6. BENELUX
15.3.1.7. United Kingdom
15.3.1.8. Rest of Europe
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Pet Type
15.3.5. By Route of Administration
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis By Region
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Indication
15.4.4. By Pet Type
15.4.5. By Route of Administration
15.4.6. By Distribution Channel
15.5. Market trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug Class
15.8.1.2.2. By Indication
15.8.1.2.3. By Pet Type
15.8.1.2.4. By Route of Administration
15.8.1.2.5. By Distribution Channel
15.8.2. France Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug Class
15.8.2.2.2. By Indication
15.8.2.2.3. By Pet Type
15.8.2.2.4. By Route of Administration
15.8.2.2.5. By Distribution Channel
15.8.3. Spain Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug Class
15.8.3.2.2. By Indication
15.8.3.2.3. By Pet Type
15.8.3.2.4. By Route of Administration
15.8.3.2.5. By Distribution Channel
15.8.4. Russia Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug Class
15.8.4.2.2. By Indication
15.8.4.2.3. By Pet Type
15.8.4.2.4. By Route of Administration
15.8.4.2.5. By Distribution Channel
15.8.5. Italy Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug Class
15.8.5.2.2. By Indication
15.8.5.2.3. By Pet Type
15.8.5.2.4. By Route of Administration
15.8.5.2.5. By Distribution Channel
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug Class
15.8.6.2.2. By Indication
15.8.6.2.3. By Pet Type
15.8.6.2.4. By Route of Administration
15.8.6.2.5. By Distribution Channel
15.8.7. United Kingdom Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug Class
15.8.7.2.2. By Indication
15.8.7.2.3. By Pet Type
15.8.7.2.4. By Route of Administration
15.8.7.2.5. By Distribution Channel
16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031
16.1. Introduction / Key Findings
16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Pet Type
16.3.5. By Route of Administration
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis By Region
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Pet Type
16.4.5. By Route of Administration
16.4.6. By Distribution Channel
16.5. Market trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug Class
16.8.1.2.2. By Indication
16.8.1.2.3. By Pet Type
16.8.1.2.4. By Route of Administration
16.8.1.2.5. By Distribution Channel
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug Class
16.8.2.2.2. By Indication
16.8.2.2.3. By Pet Type
16.8.2.2.4. By Route of Administration
16.8.2.2.5. By Distribution Channel
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug Class
16.8.3.2.2. By Indication
16.8.3.2.3. By Pet Type
16.8.3.2.4. By Route of Administration
16.8.3.2.5. By Distribution Channel
17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Thailand
17.3.1.4. Philippines
17.3.1.5. Malaysia
17.3.1.6. Vietnam
17.3.1.7. Rest of South Asia
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Pet Type
17.3.5. By Route of Administration
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis By Region
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Pet Type
17.4.5. By Route of Administration
17.4.6. By Distribution Channel
17.5. Market trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug Class
17.8.1.2.2. By Indication
17.8.1.2.3. By Pet Type
17.8.1.2.4. By Route of Administration
17.8.1.2.5. By Distribution Channel
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug Class
17.8.2.2.2. By Indication
17.8.2.2.3. By Pet Type
17.8.2.2.4. By Route of Administration
17.8.2.2.5. By Distribution Channel
17.8.3. Thailand Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug Class
17.8.3.2.2. By Indication
17.8.3.2.3. By Pet Type
17.8.3.2.4. By Route of Administration
17.8.3.2.5. By Distribution Channel
17.8.4. Philippines Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug Class
17.8.4.2.2. By Indication
17.8.4.2.3. By Pet Type
17.8.4.2.4. By Route of Administration
17.8.4.2.5. By Distribution Channel
17.8.5. Malaysia Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Drug Class
17.8.5.2.2. By Indication
17.8.5.2.3. By Pet Type
17.8.5.2.4. By Route of Administration
17.8.5.2.5. By Distribution Channel
17.8.6. Vietnam Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Drug Class
17.8.6.2.2. By Indication
17.8.6.2.3. By Pet Type
17.8.6.2.4. By Route of Administration
17.8.6.2.5. By Distribution Channel
18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031
18.1. Introduction / Key Findings
18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Pet Type
18.3.5. By Route of Administration
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis By Region
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Indication
18.4.4. By Pet Type
18.4.5. By Route of Administration
18.4.6. By Distribution Channel
18.5. Market trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug Class
18.8.1.2.2. By Indication
18.8.1.2.3. By Pet Type
18.8.1.2.4. By Route of Administration
18.8.1.2.5. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug Class
18.8.2.2.2. By Indication
18.8.2.2.3. By Pet Type
18.8.2.2.4. By Route of Administration
18.8.2.2.5. By Distribution Channel
19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. Egypt
19.3.1.4. Israel
19.3.1.5. South Africa
19.3.1.6. Northern Africa
19.3.1.7. Rest of Middle East and Africa
19.3.2. By Drug Class
19.3.3. By Indication
19.3.4. By Pet Type
19.3.5. By Route of Administration
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis By Region
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Indication
19.4.4. By Pet Type
19.4.5. By Route of Administration
19.4.6. By Distribution Channel
19.5. Market trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug Class
19.8.1.2.2. By Indication
19.8.1.2.3. By Pet Type
19.8.1.2.4. By Route of Administration
19.8.1.2.5. By Distribution Channel
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug Class
19.8.2.2.2. By Indication
19.8.2.2.3. By Pet Type
19.8.2.2.4. By Route of Administration
19.8.2.2.5. By Distribution Channel
19.8.3. Egypt Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug Class
19.8.3.2.2. By Indication
19.8.3.2.3. By Pet Type
19.8.3.2.4. By Route of Administration
19.8.3.2.5. By Distribution Channel
19.8.4. Israel Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug Class
19.8.4.2.2. By Indication
19.8.4.2.3. By Pet Type
19.8.4.2.4. By Route of Administration
19.8.4.2.5. By Distribution Channel
19.8.5. South Africa Market Analysis
19.8.5.1. Introduction
19.8.5.2. Market Analysis and Forecast by Market Taxonomy
19.8.5.2.1. By Drug Class
19.8.5.2.2. By Indication
19.8.5.2.3. By Pet Type
19.8.5.2.4. By Route of Administration
19.8.5.2.5. By Distribution Channel
19.8.6. Northern Africa Market Analysis
19.8.6.1. Introduction
19.8.6.2. Market Analysis and Forecast by Market Taxonomy
19.8.6.2.1. By Drug Class
19.8.6.2.2. By Indication
19.8.6.2.3. By Pet Type
19.8.6.2.4. By Route of Administration
19.8.6.2.5. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
20.3.1. Regional Footprint of Players
20.3.2. Product Footprint of Players
20.3.3. Channel Footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Key Development Analysis
21.3. Branding and Promotional Strategies, By Key Players
21.4. Competition Deep Dive
21.4.1. Zoetis Animal Healthcare
21.4.1.1. Overview
21.4.1.2. Product Portfolio
21.4.1.3. Key Financials
21.4.1.4. Sales Footprint
21.4.1.5. SWOT Analysis
21.4.1.6. Strategy Overview
21.4.1.6.1. Marketing Strategies
21.4.1.6.2. Channel Strategies
21.4.1.6.3. Product Strategies
21.4.2. Merck and Co.Inc. (US)
21.4.2.1. Overview
21.4.2.2. Product Portfolio
21.4.2.3. Key Financials
21.4.2.4. Sales Footprint
21.4.2.5. SWOT Analysis
21.4.2.6. Strategy Overview
21.4.2.6.1. Marketing Strategies
21.4.2.6.2. Channel Strategies
21.4.2.6.3. Product Strategies
21.4.3. Boehringer Ingelheim GmbH
21.4.3.1. Overview
21.4.3.2. Product Portfolio
21.4.3.3. Key Financials
21.4.3.4. Sales Footprint
21.4.3.5. SWOT Analysis
21.4.3.6. Strategy Overview
21.4.3.6.1. Marketing Strategies
21.4.3.6.2. Channel Strategies
21.4.3.6.3. Product Strategies
21.4.4. Elanco Animal Health Incorporated
21.4.4.1. Overview
21.4.4.2. Product Portfolio
21.4.4.3. Key Financials
21.4.4.4. Sales Footprint
21.4.4.5. SWOT Analysis
21.4.4.6. Strategy Overview
21.4.4.6.1. Marketing Strategies
21.4.4.6.2. Channel Strategies
21.4.4.6.3. Product Strategies
21.4.5. Bayer AG
21.4.5.1. Overview
21.4.5.2. Product Portfolio
21.4.5.3. Key Financials
21.4.5.4. Sales Footprint
21.4.5.5. SWOT Analysis
21.4.5.6. Strategy Overview
21.4.5.6.1. Marketing Strategies
21.4.5.6.2. Channel Strategies
21.4.5.6.3. Product Strategies
21.4.6. Vetoquinol S.A.
21.4.6.1. Overview
21.4.6.2. Product Portfolio
21.4.6.3. Key Financials
21.4.6.4. Sales Footprint
21.4.6.5. SWOT Analysis
21.4.6.6. Strategy Overview
21.4.6.6.1. Marketing Strategies
21.4.6.6.2. Channel Strategies
21.4.6.6.3. Product Strategies
21.4.7. Dechra Pharmaceuticals PLC
21.4.7.1. Overview
21.4.7.2. Product Portfolio
21.4.7.3. Key Financials
21.4.7.4. Sales Footprint
21.4.7.5. SWOT Analysis
21.4.7.6. Strategy Overview
21.4.7.6.1. Marketing Strategies
21.4.7.6.2. Channel Strategies
21.4.7.6.3. Product Strategies
21.4.8. Virbac SA
21.4.8.1. Overview
21.4.8.2. Product Portfolio
21.4.8.3. Key Financials
21.4.8.4. Sales Footprint
21.4.8.5. SWOT Analysis
21.4.8.6. Strategy Overview
21.4.8.6.1. Marketing Strategies
21.4.8.6.2. Channel Strategies
21.4.8.6.3. Product Strategies
21.4.9. IDEXX Laboratories, Inc.
21.4.9.1. Overview
21.4.9.2. Product Portfolio
21.4.9.3. Key Financials
21.4.9.4. Sales Footprint
21.4.9.5. SWOT Analysis
21.4.9.6. Strategy Overview
21.4.9.6.1. Marketing Strategies
21.4.9.6.2. Channel Strategies
21.4.9.6.3. Product Strategies
21.4.10. Ceva Santé Animale
21.4.10.1. Overview
21.4.10.2. Product Portfolio
21.4.10.3. Key Financials
21.4.10.4. Sales Footprint
21.4.10.5. SWOT Analysis
21.4.10.6. Strategy Overview
21.4.10.6.1. Marketing Strategies
21.4.10.6.2. Channel Strategies
21.4.10.6.3. Product Strategies
21.4.11. Kindred Biosciences, Inc.
21.4.11.1. Overview
21.4.11.2. Product Portfolio
21.4.11.3. Key Financials
21.4.11.4. Sales Footprint
21.4.11.5. SWOT Analysis
21.4.11.6. Strategy Overview
21.4.11.6.1. Marketing Strategies
21.4.11.6.2. Channel Strategies
21.4.11.6.3. Product Strategies
21.4.12. Phirbo Animal Health
21.4.12.1. Overview
21.4.12.2. Product Portfolio
21.4.12.3. Key Financials
21.4.12.4. Sales Footprint
21.4.12.5. SWOT Analysis
21.4.12.6. Strategy Overview
21.4.12.6.1. Marketing Strategies
21.4.12.6.2. Channel Strategies
21.4.12.6.3. Product Strategies
21.4.13. Norbrook Laboratories Limited
21.4.13.1. Overview
21.4.13.2. Product Portfolio
21.4.13.3. Key Financials
21.4.13.4. Sales Footprint
21.4.13.5. SWOT Analysis
21.4.13.6. Strategy Overview
21.4.13.6.1. Marketing Strategies
21.4.13.6.2. Channel Strategies
21.4.13.6.3. Product Strategies
21.4.14. Vetiquinol SA
21.4.14.1. Overview
21.4.14.2. Product Portfolio
21.4.14.3. Key Financials
21.4.14.4. Sales Footprint
21.4.14.5. SWOT Analysis
21.4.14.6. Strategy Overview
21.4.14.6.1. Marketing Strategies
21.4.14.6.2. Channel Strategies
21.4.14.6.3. Product Strategies
21.4.15. Neogen Corporation
21.4.15.1. Overview
21.4.15.2. Product Portfolio
21.4.15.3. Key Financials
21.4.15.4. Sales Footprint
21.4.15.5. SWOT Analysis
21.4.15.6. Strategy Overview
21.4.15.6.1. Marketing Strategies
21.4.15.6.2. Channel Strategies
21.4.15.6.3. Product Strategies
21.4.16. PetIQ, Inc.
21.4.16.1. Overview
21.4.16.2. Product Portfolio
21.4.16.3. Key Financials
21.4.16.4. Sales Footprint
21.4.16.5. SWOT Analysis
21.4.16.6. Strategy Overview
21.4.16.6.1. Marketing Strategies
21.4.16.6.2. Channel Strategies
21.4.16.6.3. Product Strategies
21.4.17. Huvepharma AD
21.4.17.1. Overview
21.4.17.2. Product Portfolio
21.4.17.3. Key Financials
21.4.17.4. Sales Footprint
21.4.17.5. SWOT Analysis
21.4.17.6. Strategy Overview
21.4.17.6.1. Marketing Strategies
21.4.17.6.2. Channel Strategies
21.4.17.6.3. Product Strategies
21.4.18. Chanelle Pharma Group Limited
21.4.18.1. Overview
21.4.18.2. Product Portfolio
21.4.18.3. Key Financials
21.4.18.4. Sales Footprint
21.4.18.5. SWOT Analysis
21.4.18.6. Strategy Overview
21.4.18.6.1. Marketing Strategies
21.4.18.6.2. Channel Strategies
21.4.18.6.3. Product Strategies
21.4.19. Kepro
21.4.19.1. Overview
21.4.19.2. Product Portfolio
21.4.19.3. Key Financials
21.4.19.4. Sales Footprint
21.4.19.5. SWOT Analysis
21.4.19.6. Strategy Overview
21.4.19.6.1. Marketing Strategies
21.4.19.6.2. Channel Strategies
21.4.19.6.3. Product Strategies
21.4.20. Biogénesis Bagó
21.4.20.1. Overview
21.4.20.2. Product Portfolio
21.4.20.3. Key Financials
21.4.20.4. Sales Footprint
21.4.20.5. SWOT Analysis
21.4.20.6. Strategy Overview
21.4.20.6.1. Marketing Strategies
21.4.20.6.2. Channel Strategies
21.4.20.6.3. Product Strategies
22. Assumptions and Acronyms Used
23. Research Methodology